Patrick Gailliot | Sr. Director, Patient Operations
Abeona Therapeutics

Patrick has spent 19 years in the pharmaceutical and biotech industries supporting companies bringing innovative therapies to market, specializing in establishing manufacturing and logistics capabilities to launch, then expand access to these therapies globally.  This includes evolving those processes to utilize new technologies.    In recent years, Patrick has worked to grow autologous manufacturing and logistics for cell and gene therapy products, including   expanding the manufacturing network for Novartis’ commercial CAR-T cell therapy Kymriah®, supporting global access internal and CDMO factories with associated supply chains, and applying those learnings to support bringing Yescarta/Tecartus® into Japan and China that supported the expansion of Kite Pharma’s commercial CAR-T programs.     Patrick has also supported companies in the early stages of building their personalized and autologous therapy programs to support the transformation of their structure for supply chains and patient operations. Recently  assisting  BioNTech in connecting its personalized clinical programs into a scalable structure that integrates there operation  across an acquired company and two acquired manufacturing locations.  Allowing them to scale those programs globally.     In his current role as Senior Director of Patient Operations at Abeona Therapeutics, Patrick tackles manufacturing and logistics challenges as the company prepares for a potential U.S. launch of its autologous cell therapy for a rare pediatric dermatological disease .    Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious and life-threatening diseases. Pz-cel, Abeona’s lead candidate, is a genetically engineered, autologous cell therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare, inherited connective tissue disease in which both copies of collagen-producing genes (Col7A1) are mutated.